Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on May 7, 2025

Exagen Inc. Announces Proposed Public Offering of Common Stock
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the …

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net …

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment …

OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first …

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights …

Emergent BioSolutions Reports First Quarter 2025 Financial Results
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an …

InnovAge Earns Recertification as a Great Place to Work
DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- InnovAge, a leading provider of Program of All-Inclusive Care for the Elderly (PACE) services, is proud to announce its recertification as a Great Place to Work®. This recognition reflects the company’s continued …

OraSure Announces First Quarter 2025 Financial Results
BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025 …

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid …

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at …

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation …

electroCore Announces First Quarter 2025 Financial Results
First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000 Company to host a conference call …

Health Catalyst Reports First Quarter 2025 Results
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended …

Clarisil Pro Under Review: Proven Hearing Loss Support Supplement with Secret Navajo Remedy
New York, May 07, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why hearing loss is on the rise—and how environmental and lifestyle factors play a major role The most common causes of auditory decline, including inflammation, nutritional …

The Honest Company Announces Appointment of Curtiss Bruce as Chief Financial Officer
LOS ANGELES, May 07, 2025 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a personal care company dedicated to creating cleanly-formulated and sustainably-designed products, today announced the appointment of Curtiss Bruce, seasoned finance …

Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined
SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first …

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …